Fulgent Therapeutics is working on a variety of new and improved treatments Read More
March 26, 2014 – Fulgent Therapeutics announces a clinical BRCA1/BRCA2 full gene sequencing test for $500. In addition to the BRCA1/BRCA2 full gene sequencing test, Fulgent Therapeutics has also added a gene rearrangement test for an additional cost of $400. For more information click on the following link. BRCA1/BRCA2 Announcement
About Us Fulgent Therapeutics, LLC is a pharmaceutical company focusing on developing and commercializing innovative cancer therapeutics and companion diagnostics. The Company has a number of improved generic and innovated drug candidates in its product pipeline for treating a broad range of cancers including breast, lung, ovarian, colon, and pancreatic cancers, along with new biomarker-based companion diagnostic tests.